aTyr Pharma
ATYR
110 hedge funds and large institutions have $336M invested in aTyr Pharma in 2025 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 28 closing their positions.
89% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 28
70% more capital inflows, than outflows
Capital inflows: $47.9M | Capital outflows: $28.2M
54% more call options, than puts
Call options by funds: $5.88M | Put options by funds: $3.81M
29% more funds holding
Funds holding: 85 → 110 (+25)
5.06% more ownership
Funds ownership: 69.5% → 74.56% (+5.1%)
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.5M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.43M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.55M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.3M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.82M |
| 3 |
Ally Bridge Group
New York
|
-$1.93M |
| 4 |
Goldman Sachs
New York
|
-$1.36M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.29M |
ATYR Hedge Fund Activity: Q2 2025 in Review
110 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2025, worth a combined $336M — up 80% from $187M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new ATYR positions and 28 closed out — a net gain of 25 holders — while 24 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $16.5M. The largest seller was Point72 Asset Management, cutting an estimated $7.3M.
- 110 institutional investors held aTyr Pharma (ATYR) as of Q2 2025, up from 85 in Q1 2025.
- Funds reported $336M of aTyr Pharma stock for Q2 2025, up 80% quarter-over-quarter.
- 53 funds opened new aTyr Pharma positions in Q2 2025 and 28 closed out, a net change of +25 holders.
- The largest aTyr Pharma buyer in Q2 2025 was BlackRock, an estimated $16.5M added.
- The largest aTyr Pharma seller in Q2 2025 was Point72 Asset Management, an estimated $7.3M sold.
Based on aggregated 13F filings for Q2 2025.